Trial: 201905032

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Phase

I

Principal Investigator

Mehta-Shah, Neha

Disease Site

Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov